The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events
Open accessAbstract
BACKGROUND: Elevated levels of C-reactive protein, even in the absence of hyperlipidemia, are associated with an increased risk of coronary events. Statin therapy reduces the level of C-reactive protein independently of its effect on lipid levels. We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia. METHODS: The level of C-reactive protein was measured at base line and after one year in 5742 participants in a five-year randomized trial of lovastatin for the primary prevention of acute coronary events. RESULTS: The rates of coronary events increased significantly with increases in the base-line levels of C-reactive protein. Lovastatin therapy reduced the C-reactive protein level by 14.8 percent (P<0.001), an effect not explained by lovastatin-induced changes in the lipid profile. As expected, lovastatin was effective in preventing coronary events in participants whose base-line ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol was higher than the median ratio, regardless of the level of C-reactive protein (number needed to treat for five years to prevent 1 event, 47; P=0.005). However, lovastatin was also effective among those with a ratio of total to HDL cholesterol that was lower than the median and a C-reactive protein level higher than the median (number needed to treat, 43; P=0.02). In contrast, lovastatin was ineffective among participants with a ratio of total to HDL cholesterol and a C-reactive protein level that were both lower than the median (number needed to treat, 983; P=0.80). CONCLUSIONS: Statin therapy may be effective in the primary prevention of coronary events among subjects with relatively low lipid levels but with elevated levels of C-reactive protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The presence of an abdominal aortic aneurysm represents a riskequivalent condition for CAD and is associated with age, male gender, personal history of atherosclerotic CVD, smoking, hypertension, and dyslipidaemia [519]; in contrast, diabetic patients are at decreased risk.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [519]
Experimental — accuracy not yet measuredIn the citing paper
“In an intriguing post hoc analysis of the AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study), investigators observed that statin therapy remained effective at mitigating risk in individuals with elevated high-sensitivity C-reactive protein but low LDL-C (28)”
From Triglycerides and residual atherosclerotic risk (2021) · cites this paper as [28]
In the citing paper
“The presence of an abdominal aortic aneurysm represents a riskequivalent condition for CAD and is associated with age, male gender, personal history of atherosclerotic CVD, smoking, hypertension, and dyslipidaemia [519]; in contrast, diabetic patients are at decreased risk.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [519]
In the citing paper
“The presence of an abdominal aortic aneurysm represents a riskequivalent condition for CAD and is associated with age, male gender, personal history of atherosclerotic CVD, smoking, hypertension, and dyslipidaemia [519]; in contrast, diabetic patients are at decreased risk.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [519]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Self-citationInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citationDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Elevated C-reactive protein levels in overweight and obese adults
Visser, M. (1999) · JAMA · doi:10.1001/jama.282.22.2131 · Cited by 2,494
Molecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,029
Köenig, W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwel, H., Döring, A., Hutchinson, W. L., & Pepys, M. B. (1999) · Circulation · doi:10.1161/01.cir.99.2.237 · Cited by 1,952
Cited by
Sorted by citations
Items 601–700 of 998
Nozue, T., Michishita, I., & Mizuguchi, I. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.1651 · Cited by 42
Brinkkoetter, P.-T., Göttmann, U., Schulte, J. H., van der Woude, F. J., Braun, C., & Yard, B. A. (2006) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2006.03217.x · Cited by 41
The regulation of ischemic acute renal failure by extrarenal organs
Kielar, M., Jeyarajah, D., & Lu, C. Y. H. (2002) · Current opinion in nephrology and hypertension · doi:10.1097/00041552-200207000-00013 · Cited by 47
Dereli, Y., Ege, E., Kurban, S., Narin, C., Sarıgül, A., & Yeniterzi, M. (2008) · Journal of International Medical Research · doi:10.1177/147323000803600611 · Cited by 40
Ferreira, J. P., Vasques‐Nóvoa, F., Neves, J. S., Zannad, F. M., & Leite-Moreira, A. F. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117461 · Cited by 41
Calza, L., Manfredi, R., Colangeli, V., Trapani, F., Salvadori, C., Magistrelli, E., Danese, I., Verucchi, G., Serra, C., & Viale, P. (2012) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2012.0015 · Cited by 40
Guasti, L., Marino, F., Cosentino, M., Cimpanelli, M., Maio, R. C., Klersy, C., Crespi, C., Restelli, D., Simoni, C., Franzetti, I., et al. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000251903.62804.77 · Cited by 40
Antiarrhythmic Mechanisms of n-3 PUFA and the Results of the GISSI-Prevenzione Trial
Marchioli, R., Levantesi, G., Macchia, A., Maggioni, A. P., Marfisi, R. M., Silletta, M. G., Tavazzi, L., Tognoni, G., & Valagussa, F. (2005) · The Journal of Membrane Biology · doi:10.1007/s00232-005-0788-x · Cited by 39
Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives
Patoulias, D., Stavropoulos, K., Imprialos, K. P., Athyros, V. G., Grassos, H., Doumas, M. N., & Faselis, C. J. (2020) · Current Vascular Pharmacology · doi:10.2174/1570161118666200318104434 · Cited by 41
NHG-Standaard Cardiovasculair risicomanagement
Wiersma, T., Boukes, F., Geijer, R. M. M., & Goudswaard, A. N. (2009) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-6614-9_6 · Cited by 40
Regulation of different inflammatory diseases by impacting the mevalonate pathway
Zeiser, R., Maas‐Bauer, K., Youssef, S., Dürr, C., Steinman, L., & Negrin, R. S. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.03011.x · Cited by 42
Lipid levels do not influence the risk of venous thromboembolism
Mahmoodi, B. K., Gansevoort, R. T., Muntinghe, F. L. H., Dullaart, R. P. F., Kluin‐Nelemans, H. C., Veeger, N. J. G. M., van Schouwenburg, I. M., & Meijer, K. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-06-0426 · Cited by 40
Efrati, S., Averbukh, M., Dishy, V., Faygenzo, M., Friedensohn, L., & Golik, A. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0238-4 · Cited by 40
C-Reactive Protein and Peripheral Artery Disease among Japanese Elderly: the Tsurugaya Project
Hozawa, A., Ohmori, K., KURIYAMA, S., Shimazu, T., Niu, K., Watando, A., Ebihara, S., Matsui, T., Ichiki, M., Nagatomi, R., et al. (2004) · Hypertension Research · doi:10.1291/hypres.27.955 · Cited by 40
Mach, F. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s2706 · Cited by 40
Chapter 3 Effect of Hormone Replacement Therapy on Inflammatory Biomarkers
Γεωργιάδου, Π., & Sbarouni, E. (2009) · Advances in clinical chemistry · doi:10.1016/s0065-2423(09)47003-3 · Cited by 38
Tousoulis, D., Antoniades, C. A., Katsi, V. K., Bosinakou, E., Kotsopoulou, M., Tsioufis, C. P., & Stefanadis, C. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.05.055 · Cited by 40
Aktaş, O., Waiczies, S., & Zipp, F. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.026 · Cited by 40
Piñón-Esteban, P., & Kaski, J. C. (2006) · Revista Española de Cardiología · doi:10.1157/13086082 · Cited by 40
Emerging role of various signaling pathways in the pathogenesis and therapeutics of atherosclerosis
Prashar, Y., Ritu, R., Bais, S., & Gill, N. S. (2017) · Reviews in vascular medicine · doi:10.1016/j.rvm.2017.05.001 · Cited by 38
Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia
Onder, G., Vedova, C. D., & Landi, F. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0209-4 · Cited by 39
ApoB/ApoA-I ratio in young patients with ischemic cerebral stroke or peripheral arterial disease
Sabino, A. D. P., Sousa, M. O., Lima, L. M., Ribeiro, D. D., Dusse, L. M. S., Ferriani, M. D. G. C., & Fernandes, A. P. (2008) · Translational research · doi:10.1016/j.trsl.2008.06.005 · Cited by 39
Ikeda, M., Takeshima, F., Isomoto, H., Shikuwa, S., Mizuta, Y., Ozono, Y., & Kohno, S. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-0102-0 · Cited by 39
Pirro, M., Mannarino, M. R., Ministrini, S., Fallarino, F., Lupattelli, G., Bianconi, V., Bagaglia, F., & Mannarino, E. (2016) · Scientific Reports · doi:10.1038/srep23587 · Cited by 39
Jolly, A., Lu, S., Strand, K. A., Dubner, A., Mutryn, M. F., Nemenoff, R. A., Majesky, M. W., Moulton, K. S., & Weiser‐Evans, M. C. M. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab174 · Cited by 39
The Role of Statins in the Setting of HIV Infection
Eckard, A. R., & McComsey, G. A. (2015) · Current HIV/AIDS Reports · doi:10.1007/s11904-015-0273-9 · Cited by 38
Samnegård, A., Hulthe, J., Silveira, A. M. V., Ericsson, C.-G., Hamsten, A., & Eriksson, P. O. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.05.050 · Cited by 39
Devaraj, S., Autret, B. C., & Jialal, I. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.03.043 · Cited by 39
The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis
Yu, M., Tsai, S., & Kuo, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061260 · Cited by 39
Role of Infection in Atherosclerosis and Coronary Artery Disease: A New Therapeutic Target?
Frishman, W. H., & ISMAIL, A. (2002) · Cardiology in Review · doi:10.1097/00045415-200207000-00004 · Cited by 39
Bays, H. E., Stein, E. A., Shah, A. K., Maccubbin, D., Mitchel, Y., & Mercuri, M. F. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02658-9 · Cited by 39
Blake, G. J., Ridker, P. M., & Kuntz, K. M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01914-9 · Cited by 39
Self-citationLee, K. H., Park, H. W., Cho, J. G., Yoon, N. S., Kim, S. S., Kim, J.-H., Kim, M. C., Cho, K. H., Kim, H. K., Kim, C. H., et al. (2015) · EP Europace · doi:10.1093/europace/euv210 · Cited by 38
Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy
Liang, M., Yang, S., & Fu, N. (2017) · Medicine · doi:10.1097/md.0000000000007384 · Cited by 38
Update on C-reactive protein as a risk marker in cardiovascular disease
Köenig, W. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s84.22.x · Cited by 38
Ali, R., & Alexander, K. P. (2007) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2007.03.008 · Cited by 38
Role of Infectious and Immune Factors in Coronary and Cerebrovascular Arteriosclerosis
Stöllberger, C., & Finsterer, J. (2002) · Clinical and Vaccine Immunology · doi:10.1128/cdli.9.2.207-215.2002 · Cited by 38
Markers of preclinical atherosclerosis and their clinical relevance
Poredoš, P., & Jezovnik, M. K. (2015) · VASA · doi:10.1024/0301-1526/a000439 · Cited by 37
Veselka, J., Procházková, Š., Duchoňová, R., Bolomová, I., Urbanová, T., Tesař, D., & Honĕk, T. (2002) · Coronary Artery Disease · doi:10.1097/00019501-200205000-00003 · Cited by 38
The Role of C-reactive Protein in Patient Risk Stratification and Treatment
Arroyo‐Espliguero, R., Viana-Llamas, M. C., Silva, J. A., & y, P. A. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.49 · Cited by 41
Gersh, B. J., Tsang, T. S. M., & Seward, J. B. (2004) · PubMed Central · Cited by 37
Schneider, M. P., Schmidt, B. M. W., John, S., & Schmieder, R. E. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834a509a · Cited by 37
Inflammation and coagulation in atherosclerosis
Krychtiuk, K. A., Kastl, S., Wojta, J., & Speidl, W. S. (2013) · Hämostaseologie · doi:10.5482/hamo-13-07-0039 · Cited by 37
The erythrocyte adhesiveness/aggregation test (EAAT)
Rotstein, R., Landau, T., Twig, A., Rubinstein, A., Koffler, M., Justo, D., Constantiner, D., Zeltser, D., Shapira, I., Mardi, T., et al. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00250-2 · Cited by 37
Rao, M., Jaber, B. L., & Balakrishnan, V. S. (2006) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2006.00138.x · Cited by 37
Dağlı, N., Yavuzkır, M., & Karaca, I. (2007) · Inflammation · doi:10.1007/s10753-007-9041-3 · Cited by 37
Should Years of Schooling Be Used to Guide Treatment of Coronary Risk Factors?
Fiscella, K. A. (2004) · The Annals of Family Medicine · doi:10.1370/afm.88 · Cited by 37
Hong, Y. J., Jeong, M. H., Lim, S. Y., Lee, S. R., Kim, K. H., Sohn, I. S., Park, H. W., Kim, J. H., Kim, W., Ahn, Y., et al. (2005) · Circulation Journal · doi:10.1253/circj.69.1477 · Cited by 37
Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs
Lincoff, A. M., Ray, K. K., Sasiela, W. J., Haddad, T. M., Nicholls, S. J., Li, N., Cho, L., Mason, D., Libby, P., Goodman, S. G., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.048 · Cited by 44
Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort
Swede, H., Hajduk, A. M., Sharma, J., Rawal, S., Rasool, H., Vella, A. T., Tobet, R. E., & Stevens, R. G. (2013) · International Journal of Cancer · doi:10.1002/ijc.28504 · Cited by 36
Meroni, P. L., Luzzana, C., & Ventura, D. (2002) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:23:3:263 · Cited by 35
Genetic Polymorphisms in Cytochrome P450 Enzymes
Vermes, A., & Vermes, I. (2004) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200404040-00005 · Cited by 36
Changes in C‐reactive Protein Plasma Levels During Low‐density Lipoprotein Apheresis
Kojima, S., Shida, M., & Yokoyama, H. (2003) · Therapeutic Apheresis and Dialysis · doi:10.1046/j.1526-0968.2003.00080.x · Cited by 36
Myerburg, R. J., Interian, A., Simmons, J. D., & Castellanos, A. (2004) · Elsevier eBooks · doi:10.1016/b0-7216-0323-8/50081-6 · Cited by 36
Emerging anti-inflammatory drugs for atherosclerosis
Berman, J. P., Farkouh, M. E., & Rosenson, R. S. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.801453 · Cited by 35
Cardiovascular Risk Assessment
Pletcher, M. J., & Moran, A. E. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.03.002 · Cited by 42
Ritz, E., Dikow, R., Adamzcak, M., & Zeier, M. G. (2002) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2002.00044.x · Cited by 35
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
Liao, J. K. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0037-3 · Cited by 35
McGillicuddy, F. C., Lynch, I., Rochev, Y. A., Burke, M., Dawson, K. A., Gallagher, W. M., & KEENAN, A. K. (2006) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.30839 · Cited by 35
Targeting inflammation to slow or delay functional decline: where are we?
Corsonello, A., Garasto, S., Abbatecola, A. M., Rose, G., Passarino, G., Mazzei, B., Pranno, L., Guffanti, E. E., Bustacchini, S., & Lattanzio, F. (2010) · Biogerontology · doi:10.1007/s10522-010-9289-0 · Cited by 35
The potential for novel anti-inflammatory therapies for coronary artery disease
Cascieri, M. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd723 · Cited by 35
Bloomgarden, Z. T. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2342 · Cited by 35
Lin, G., Liu, K., Colangelo, L. A., Lakoski, S. G., Tracy, R. P., & Greenland, P. (2015) · American Journal of Epidemiology · doi:10.1093/aje/kwv144 · Cited by 35
The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: Part I
Armani, A. M., & Becker, R. C. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.12.031 · Cited by 35
Current and future concepts in stroke prevention
O’Rourke, F. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1031185 · Cited by 34
Siest, G., Marteau, J., Maumus, S., Berrahmoune, H., Jeannesson, É., Samara, A., Batt, A., & Visvikis‐Siest, S. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.10.011 · Cited by 35
Xiong, Y., Xie, S., Yao, Y., Chen, Y., Ding, J.-H., Zhou, R., Liu, W.-Y., Zhang, Y., Wang, L., & Liu, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-79520-x · Cited by 30
Effects of niacin on atherosclerosis and vascular function
Ruparelia, N., Digby, J. E., & Choudhury, R. P. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283410c16 · Cited by 35
Inflammation of carotid plaques and risk of cerebrovascular events
Poredoš, P., Gregorič, I. D., & Jezovnik, M. K. (2020) · Annals of Translational Medicine · doi:10.21037/atm-2020-cass-15 · Cited by 34
Huang, Y.-C., Lin, Y., Chang, J. ‐., Chen, S., Wan, L., Sheu, J. J., Lai, C., Lin, C., Liu, S., Chen, C. ‐., et al. (2010) · International Journal of Immunogenetics · doi:10.1111/j.1744-313x.2010.00943.x · Cited by 33
Das, T., Mandal, C., & Mandal, C. (2003) · Glycoconjugate Journal · doi:10.1023/b:glyc.0000043290.90182.e6 · Cited by 34
The Role and Clinical Significance of High-Sensitivity C-Reactive Protein in Cardiovascular Disease
Seo, H. S. (2012) · Korean Circulation Journal · doi:10.4070/kcj.2012.42.3.151 · Cited by 35
Statins: can the new generation make an impression?
Rosenson, R. S. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.2.269 · Cited by 35
Dyslipidemia and the vulnerable plaque
Farmer, J. A., & Gotto, A. M. (2002) · Progress in Cardiovascular Diseases · doi:10.1053/pcad.2002.123474 · Cited by 34
Self-citationC‐reactive protein lowering with rosuvastatin in the METEOR study
Peters, S. A. E., Palmer, M. K., Grobbee, D. E., Crouse, J. R., O’Leary, D. H., Raichlen, J. S., & Bots, M. L. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02230.x · Cited by 33
O’Donoghue, M. L., Glaser, R., Aylward, P. E., Cavender, M. A., Crisp, A., Fox, K. A. A., Laws, I., López-Sendón, J. L., Steg, P. G., Théroux, P., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.02.012 · Cited by 33
Functionality of C-Reactive Protein for Atheroprotection
Singh, S. K., & Agrawal, A. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01655 · Cited by 36
Bergqvist, R., Ahlqvist, V. H., Lundberg, M., Hergens, M., Sundström, J., Bell, M., & Magnusson, C. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003820 · Cited by 33
Csordás, A., Wick, G., Laufer, G., & Bernhard, D. (2008) · Biomarker Insights · doi:10.4137/bmi.s480 · Cited by 33
Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk
Glueck, C. J., & Goldenberg, N. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3241 · Cited by 33
Inflammatory predictors of mortality in the scandinavian simvastatin survival study
Crea, F., Monaco, C. G., Lanza, G. A., Maggi, E., Ginnetti, F., Cianflone, D., Niccoli, G., Cook, T. J., Bellomo, G., & KJEKSHUS, J. K. (2002) · Clinical Cardiology · doi:10.1002/clc.4960251005 · Cited by 33
Inflammation, infection, and atherosclerosis
Fahdi, I. E., Gaddam, V., Garza, L., Romeo, F., & Mehta, J. L. (2003) · Brain Behavior and Immunity · doi:10.1016/s0889-1591(03)00052-7 · Cited by 33
Flemming, K. D., & Brown, R. D. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.10.1330 · Cited by 33
Ošťádal, P., Alan, D., Hájek, P., Horak, D., Vejvoda, J., Trefanec, J., Mates, M., & Vojáček, J. (2003) · Springer eBooks · doi:10.1007/978-1-4615-0298-2_7 · Cited by 33
Modena, M. G., Bursi, F., Fantini, G., Cagnacci, A., Carbonieri, A., Fortuna, A., & Rossi, R. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01209-3 · Cited by 33
Do Statins Have Antidepressant Effects?
Köhler-Forsberg, O., Gasse, C., Berk, M., & Østergaard, S. D. (2017) · CNS Drugs · doi:10.1007/s40263-017-0422-3 · Cited by 31
Liu, J., & Wang, J. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1180912 · Cited by 33
Ma, J., & Chen, X. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.631398 · Cited by 36
Kazeros, A., Zhang, E., Cheng, X., Shao, Y., Liu, M., Qian, M., Caplan‐Shaw, C., Berger, K. I., Goldring, R. M., Ghumman, M., et al. (2015) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000000458 · Cited by 32
Srivastava, R. A. K., Mistry, S., & Sharma, S. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0018-1 · Cited by 32
The importance of total cardiovascular risk assessment in clinical practice
Graham, I. M. (2006) · European Journal of General Practice · doi:10.1080/13814780600976282 · Cited by 32
Radiographic Contrast-Media-Induced Acute Kidney Injury: Pathophysiology and Prophylactic Strategies
Sadat, U. (2013) · ISRN Radiology · doi:10.5402/2013/496438 · Cited by 33
What causes acute coronary syndromes? Applying Koch's postulates
Monaco, C. G., Mathur, A., & Martin, J. F. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.10.022 · Cited by 32
Issues surrounding age: vascular disease in the elderly
Shepherd, J. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200112000-00002 · Cited by 32
Cholesterol, Cytokines and Diseases
Saggini, A., Anogeianaki, A., Maccauro, G., Tetè, S., Salini, V., Caraffa, A., Conti, F., Fulcheri, M., Galzio, R. J., & Shaik-Dasthagirisaheb, Y. B. (2011) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201102400303 · Cited by 32
Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications
Montarello, N. J., Nguyen, M. T., Wong, D. T. L., Nicholls, S. J., & Psaltis, P. J. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07106-6 · Cited by 66
Ambient Particulate Matter, C-Reactive Protein, and Coronary Artery Disease
Sandhu, R. S., Petroni, D., & George, W. J. (2005) · Inhalation Toxicology · doi:10.1080/08958370590929538 · Cited by 31
Matsubara, T., Naruse, K., Arakawa, T., Nakao, M., Yokoi, K., Oguri, M., Marui, N., Amano, T., Ichimiya, S., Ohashi, T., et al. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.07.012 · Cited by 31
Blum, A. (2014) · BioFactors · doi:10.1002/biof.1157 · Cited by 31
Vallianou, N. G., Tsang, C., Taghizadeh, M., Davoodvandi, A., & Jafarnejad, S. (2018) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2018.12.005 · Cited by 31
Metadata
- Authors
- Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- University of North Texas Health Science Center (US)
- Wilford Hall Ambulatory Surgical Center (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-06-28
- Volume
- 344
- Issue
- 26
- Pages
- 1959-1965
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2316243284
- Cited by
- 1,557
- References
- 27
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 16 · 2023: 29 · 2022: 34 · 2021: 30 · 2020: 35 · 2019: 38 · 2018: 29 · 2017: 25 · 2016: 39 · 2015: 41 · 2014: 39 · 2013: 43 · 2012: 52
- FWCI
- 158.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Doris Duke Charitable Foundation
- American Heart Association
- Fondation Leducq
- National Heart, Lung, and Blood Institute (R01HL058755, HL-58755)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- C-reactive protein, statin therapy, lovastatin, primary prevention, acute coronary events, cardiovascular risk stratification, TC/HDL-C ratio, hyperlipidemia, inflammation, number needed to treat
- MeSH terms
- Acute Disease, Anticholesteremic Agents, C-Reactive Protein, Cholesterol, Coronary Disease, Double-Blind Method, Follow-Up Studies, Humans, Cholesterol, HDL, Lovastatin, Primary Prevention, Risk, Risk Factors, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
